Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Stock Day Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stock Day Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Rosinbomb | CSL & Arcturus Therapeutics Holdings Inc.
MP3•Episode home
Manage episode 418340609 series 180440
Content provided by Stock Day Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stock Day Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Rosinbomb (OTC:ROSN) proudly announces a significant patent filing, showcasing the unique and proprietary air circulation system of the Nature Fresh Freeze Dryer. This innovation includes a revolutionary Piezo electric fan system seamlessly integrated into their innovative honeycomb rack system, optimizing airflow and enabling customers to process nearly twice the amount of material in the same time.
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
1487 episodes
MP3•Episode home
Manage episode 418340609 series 180440
Content provided by Stock Day Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stock Day Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Rosinbomb (OTC:ROSN) proudly announces a significant patent filing, showcasing the unique and proprietary air circulation system of the Nature Fresh Freeze Dryer. This innovation includes a revolutionary Piezo electric fan system seamlessly integrated into their innovative honeycomb rack system, optimizing airflow and enabling customers to process nearly twice the amount of material in the same time.
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant.
For more information, please visit StockDayMedia.com
1487 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.